Chief Medical Officer

Hartmann Young; Massachusetts; Hybrid; USD 250,000 - 350,000; Full time

Benefits offered by this job

Strong equity and long-term upside

Flexible remote/hybrid model

Job summary

A biotechnology firm in the East Coast USA is looking for a Chief Medical Officer to lead clinical strategy for solid tumor cell therapies. The ideal candidate will have an MD and over 8 years of experience in clinical development. This role offers a hybrid or remote work model and significant equity opportunities in a high-growth environment.

Qualifications

• 8+ years in clinical development.
• Proven track record in solid tumor trials.
• Experience in cell therapy preferred (e.g., iPSC, NK, TCR, γδ T cells).

Responsibilities

• Lead clinical strategy for solid tumor cell therapies.
• Oversee regulatory engagement and IND strategy.
• Collaborate with executives on development milestones.

Skills

Clinical strategy leadership

Regulatory engagement

FDA interactions

Solid tumor trial expertise

IND strategy

Education

MD

Job description

Overview

Chief Medical Officer – Solid Tumor Cell Therapy

East Coast USA | Hybrid or Remote

I'm partnering exclusively with a well-funded, next-gen cell therapy biotech developing non–CAR-T therapies for solid tumors. With a lead asset entering clinical development, they’re seeking a CMO to lead clinical strategy, FIH trials, and regulatory engagement through to late-stage development.

Responsibilities

• Lead clinical strategy, first-in-human trials, and late-stage development plans for solid tumor cell therapies.
• Oversee regulatory engagement, IND strategy and interactions with the FDA.
• Collaborate with the executive team to shape development milestones and go-to-market timing.

Qualifications

• MD required.
• 8+ years in clinical development.
• Proven track record in solid tumor trials.
• Experience in cell therapy; experience in NON CAR-T cell therapy preferred (e.g., iPSC, NK, TCR, γδ T cells).
• Strong FDA interaction and IND leadership.

Why Join

• Shape the future of solid tumor cell therapy.
• Join an elite, science-led executive team.
• Strong equity and long-term upside.
• Flexible remote/hybrid model from East Coast.